Table 3.

Clinical outcomes in patients who were treated with GA continuously and in those who discontinued GA treatment

Population	Patients taking GA continuously	Patients discontinuing GA	Patients taking GA continuously	Patients discontinuing GA
Follow-up period	Until last FU visit	Until last FU	At 5 years	At 5 years
	N = 395	N = 457	N = 269	N = 325
Annualised exacerbation rate (mean [95% CI])	0.28 [0.23; 0.33]	0.63 [0.56; 0.71]a	0.23 [0.19; 0.26]	0.51 [0.46; 0.56]a
Exacerbation-free throughout the follow-up period (% [95% CI])	201 (50.9%) [46.0%; 55.8%]	118 (25.8%)a [21.8%; 29.8%]	127 (47.2%) [41.2%; 53.2%]	64 (19.7%)a [15.4%; 24.0%]
Evolution of EDSS score (mean [95% CI])b	0.26 [0.14; 0.39]	0.78 [0.63; 0.93]a	0.24 [0.09; 0.40]	0.80 [0.62; 0.97]a
Patients with no EDSS evolution (% [95% CI])b	163/322 (50.6%) [45.2%; 56.1%]	128/387 (33.1%)a [28.4%; 37.8%]	109/226 (48.2%) [41.7%; 54.7%]	79/281 (28.1%)a [22.9%; 33.4%]

^aSignificant difference with patients continually taking GA (p < 0.0001; χ² test for categorical variables and Student’s t test for continuous variables)

^bThese variables could only be assessed in patients evaluated at least 3 months distant from an exacerbation